Treatment of Hemophilia A

JP2025508043A5Pending Publication Date: 2026-03-16BIOVERATIV THERAPEUTICS INC
0 Cites 0 Cited by

Patent Information

Application Number
JP2024553326
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-06
Filing Date
2023-03-07
Publication Date
2026-03-16

AI Technical Summary

Technical Problem

In the prior art, patients with hemophilia A need to frequently inject coagulation factor VIII, and the activity threshold of the existing coagulation factor VIII products is insufficient, which cannot effectively prevent and control bleeding events, resulting in patients suffering from severe bleeding complications and a decline in quality of life for a long time.

Method used

A choline protein consisting of FVIII protein and VWF fragments, including the VWF fragments of the D'd' and D3 domains, is developed, through the use of this choline protein, able to prolong the half-life of coagulation factor VIII, reduce the frequency of injection, and increase the activity level of coagulation factor VIII.

Benefits of technology

Through this method, the frequency and severity of bleeding in patients with hemophilia A can be significantly reduced, the quality of life of patients can be improved, and the cost of medical care can be reduced.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides a method for treating hemophilia A in a human subject in need of such treatment, comprising administering to the subject a chimeric protein comprising (i) a factor VIII (FVIII) protein and (ii) a von Willebrand factor (VWF) fragment comprising the D' domain of VWF and the D3 domain of VWF.
Need to check novelty before this filing date? Find Prior Art